Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations.

Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations. - HER2-CS STUDY

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017003

Enrollment

1000

Registered

2015-04-01

Start date

2015-01-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Non-small cell lung cancer with pathological confirmation 2. No radical treatment indication 3. Performance status 0-2 4. Patient with document agreement for this study

Exclusion criteria

Exclusion criteria: There are no special instruction regarding this section.

Design outcomes

Primary

Measure	Time frame
Develpment of the criteria of HER2 postivity in NSCLC	—

Countries

Japan

Contacts

Public ContactKatsuyuki Hotta

Okayama University Hospital Allergy and respiratory medicine

khotta@md.okayama-u.ac.jp086-235-7227

Outcome results